136 related articles for article (PubMed ID: 38136324)
1. Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.
Zhu M; Taylor WR; Mahoney DW; Then SS; Berger CK; Burger KN; Gonser AM; Doering KA; Xie H; Foote PH; Kaiser MW; Allawi HT; Hubbard JM; Kisiel JB
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136324
[TBL] [Abstract][Full Text] [Related]
2. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.
Xie H; Mahoney DW; Foote PH; Burger KN; Doering KA; Taylor WR; Then SS; Cao X; McGlinch M; Berger CK; Wu TT; Hubbard JM; Allawi HT; Kaiser MW; Lidgard GP; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 Jan; 27(1):141-149. PubMed ID: 33028593
[TBL] [Abstract][Full Text] [Related]
3. Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients.
Chan HT; Nagayama S; Otaki M; Chin YM; Fukunaga Y; Ueno M; Nakamura Y; Low SK
Front Oncol; 2022; 12():1055968. PubMed ID: 36776372
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
5. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
6. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery.
Dhiman A; Kothary V; Witmer HDD; Bregio C; Sood D; Ong CT; Polite B; Eng OS; Shergill A; Turaga KK
Ann Surg; 2023 Dec; 278(6):925-931. PubMed ID: 36994703
[TBL] [Abstract][Full Text] [Related]
7. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
8. Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.
Pedersen SK; Musher BL; LaPointe LC; Tuck MK; Symonds EL; Loayza N; Young GP
Cancer; 2022 May; 128(10):1921-1928. PubMed ID: 35290664
[TBL] [Abstract][Full Text] [Related]
9. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.
Kisiel JB; Dukek BA; V S R Kanipakam R; Ghoz HM; Yab TC; Berger CK; Taylor WR; Foote PH; Giama NH; Onyirioha K; Abdallah MA; Burger KN; Slettedahl SW; Mahoney DW; Smyrk TC; Lewis JT; Giakoumopoulos M; Allawi HT; Lidgard GP; Roberts LR; Ahlquist DA
Hepatology; 2019 Mar; 69(3):1180-1192. PubMed ID: 30168613
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Circulating Tumor DNA for Methylated
Musher BL; Melson JE; Amato G; Chan D; Hill M; Khan I; Kochuparambil ST; Lyons SE; Orsini J; Pedersen SK; Robb B; Saltzman J; Silinsky J; Gaur S; Tuck MK; LaPointe LC; Young GP
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2702-2709. PubMed ID: 32958500
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.
Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL
Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma.
Qin Y; Wu CW; Taylor WR; Sawas T; Burger KN; Mahoney DW; Sun Z; Yab TC; Lidgard GP; Allawi HT; Buttar NS; Smyrk TC; Iyer PG; Katzka DA; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2019 Dec; 25(24):7396-7404. PubMed ID: 31527170
[TBL] [Abstract][Full Text] [Related]
15. Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.
Anderson BW; Suh YS; Choi B; Lee HJ; Yab TC; Taylor WR; Dukek BA; Berger CK; Cao X; Foote PH; Devens ME; Boardman LA; Kisiel JB; Mahoney DW; Slettedahl SW; Allawi HT; Lidgard GP; Smyrk TC; Yang HK; Ahlquist DA
Clin Cancer Res; 2018 Nov; 24(22):5724-5734. PubMed ID: 29844130
[No Abstract] [Full Text] [Related]
16. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
17. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence.
Pedersen SK; Symonds EL; Roy AC; Cornthwaite KJ; LaPointe LC; Young GP
Cancer Med; 2023 Jan; 12(2):1319-1329. PubMed ID: 35822405
[TBL] [Abstract][Full Text] [Related]
18. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
[TBL] [Abstract][Full Text] [Related]
19. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
20. Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study.
Yamashita K; Waraya M; Kim MS; Sidransky D; Katada N; Sato T; Nakamura T; Watanabe M
PLoS One; 2014; 9(12):e113546. PubMed ID: 25469504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
